GlassScriptPhysician profile
Mansumeet Singh
NPI 1902113368
$3,850.29
in general payments reported to CMS, 2019-2025
30 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $136 · 2021: $246 · 2022: $446 · 2023: $538 · 2024: $1,218 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388 · Education: $78.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.65 |
| Education | $78.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.27 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $363.04 | 2022-2025 | Tarpeyo |
| Amgen INC. | $359.15 | 2019-2025 | Tavneos |
| Vifor Pharma, INC. | $331.39 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $222.85 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $206.40 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $205.81 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $199.35 | 2020-2024 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $195.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.71 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $165.84 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $116.68 | 2022-2025 | Ultomiris |
| Ardelyx, INC. | $105.98 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $98.72 | 2019-2025 | Injectafer |
| Akebia Therapeutics INC | $86.58 | 2023-2025 | Auryxia, Vafseo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $68.26 | 2019 | |
| Novo Nordisk INC | $66.86 | 2024-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $63.55 | 2019-2025 | Rayaldee |
| Corcept Therapeutics | $61.47 | 2024-2025 | Korlym |
| Genentech USA, INC. | $48.75 | 2019-2025 | Gazyva |
| Lilly USA, LLC | $32.91 | 2021-2024 | Jardiance |
| Endo Pharmaceuticals INC. | $26.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.82 | 2024 | Purified Cortrophin Gel |
| Shire North American Group INC | $23.24 | 2019 | |
| Horizon Therapeutics Plc | $23.13 | 2023 | Krystexxa |
| Baxter Healthcare | $20.15 | 2019 | |
| Aurinia Pharma U.S., INC. | $18.97 | 2024 | Lupkynis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2020 | |
| Scpharmaceuticals INC. | $14.86 | 2023 | |
| Kyowa Kirin, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansumeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.